“A lot of people have H. pylori, but very few have bad outcomes. Is that due to the organism or the host?” says Martin Blaser, a microbiologist at New York University School of Medicine. “This paper provides evidence that the fit is important. It’s a very nice advance.”

The study led by Pelayo Correa and Scott Williams at Vanderbilt University Medical Center in Nashville, Tennessee, has shown that this mismatch can turn a normally benign infection into a potentially carcinogenic one. When analysed together, the genomes of hosts and microbes give a better prediction of the risk of disease than when considered alone, the team found. Their results were published in Proceedings of the National Academy of Sciences.

For original article, please see:http://www.nature.com/news/human-microbe-mismatch-boosts-risk-of-stomach-cancer-1.14501.

特别申明：文章原引内容及涉及字体图片等素材版权归原作者所有。本文章内容仅用于学习及学术交流，不做任何商业用途。

About TenNor Therapeutics

Incorporated in 2013, TenNor Therapeutics is a near-commercial stage biotechnology company dedicated to the discovery, development and commercialization of differentiated therapies to address unmet medical needs in disease areas associated with bacterial infections and bacterial metabolism. Empowered by its proprietary multi-targeting conjugate molecule technology, TenNor Therapeutics aims to deliver the best therapeutic solutions to overcome the limitations of conventional treatments and improve patient outcomes. As of January 24, 2026, TenNor Therapeutics had built a pipeline of seven innovative programs, including two Core Products, namely, rifasutenizol (TNP-2198), a new molecular entity (“NME”) drug candidate used as part of a triple therapy in combination with amoxicillin and a proton pump inhibitor for the treatment of Helicobacter pylori (“H. pylori”) infection in China and U.S. as well as monotherapy for bacterial vaginosis and C. difficile infection in China; and rifaquizinone (TNP-2092 injection), a triple-targeting antibacterial drug candidate for the treatment of implant-associated bacterial infections, i.e. acute bacterial skin and skin structure infection (“ABSSSI”) and prosthetic joint infection (“PJI”), as well as left ventricular assist device infection (“LVADI”) and catheter-related bloodstream infection (“CRBSI”) in China and the U.S.

For more information, please visit: www.tennortherapeutics.com